Liquidia (LQDA) Capital Expenditures Growth (3y) (2023 - 2026)
Liquidia (LQDA) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.85 Bn | 32.11 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.52 Bn | 30.58 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.30 Bn | 18.50 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.59 Bn | 12.16 Bn | 785.00 Mn | 28.56% |
| 10 | Liquidia | 7.61 Bn | 7.39 Bn | 121.79 Mn | 162.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 162.05% |
| Dec 31, 2025 | -27.89% |
| Sep 30, 2025 | 113.20% |
| Jun 30, 2025 | -566.65% |
| Mar 31, 2025 | 950.11% |
| Dec 31, 2024 | -458.86% |
| Jun 30, 2024 | -47.46% |
| Mar 31, 2024 | 180.86% |
| Dec 31, 2023 | 36.27% |
| Sep 30, 2023 | 5.87% |
| Jun 30, 2023 | 336.21% |
| Mar 31, 2023 | 395.97% |